Background: Costimulatory and cellular adhesion molecules are thought to be essential components of antigen presentation in the immune response to cancer. The current studies examine gene transfer utilizing herpes viral amplicon vectors (HSV) to direct surface expression of adhesion molecules, and specifically evaluate the potential of a tumor-expressing intercellular adhesion molecule- 1 
Introduction
Cell-cell adhesion is central to an effective immune interaction between T cells and targets (1) .
Intercellular adhesion molecule-I (ICAM-1) is a well-described adhesion molecule that mediates cell adhesion through a receptor on leukocytes known as leukocyte function antigen-I (LFA-1) (2, 3) . Baseline in vivo expression of ICAM-1 is usually low and limited to endothelial cells, lymphoid cells and fibroblasts. ICAM-I expression is up-regulated in inflammatory states in vivo and by interleukin-1 (IL-1), tumor necrosis factor a (TNFa), and interferon y (IFN-,y) in vitro (4, 5) . There is mounting evidence that ICAM-1 /LFA-1-mediated cell adhesion plays a critical role in the binding of T lymphocytes and may participate in immune activation. A series of studies have shown that monoclonal antibodies directed at ICAM-1 can inhibit cytotoxic T lymphocyte (CTL), natural killer (NK), and lymphokine activated killer (LAK) cell-mediated lysis of targets in vitro (6) (7) (8) (9) . Furthermore, transfection of the ICAM-1 gene into major histocompatibility complex (MHC)-deficient fibroblasts enhances stimulation of T cells (10) . It has recently been postulated that the loss of ICAM-1 expression on the surface of tumor cells may be responsible for certain tumors' ability to evade the host immune system (11) (12) (13) . Enhancement of expression of cell adhesion molecules such as ICAM-1, therefore, represents a potential strategy for therapeutic manipulation of anti-tumor immunity (14, 15 Human lymphocytes were then harvested as previously described (24) . Briefly, 15 cc of fresh heparinized blood was harvested from healthy human volunteers. The blood was mixed with an equal amount of PBS, and 9 cc of Ficoll-Paque (endotoxin tested, sterile; Amersham Pharmacia Biotech, Piscataway, NJ) was then layered beneath the mixture, and the gradient centrifuged at 2000 rpm, 200C, for 30 min with no brake (Eppendorf, model 5810R). The monocellular layer was then harvested and washed twice in HBSS in a v:v ratio of 3:1. The cells were incubated overnight in complete RPMI (.01 mM NEAA, 1 mM NaPyruvate, 2 mM L-glutamine, 50 ,uM 2-ME, penicillin/streptomycin) containing 10% FCS, 50 U/ml IL-2 (R&D Systems), 5 ,ug/ml Con A (Sigma), and 50 ng/ml PMA.
Before MTT-labeled lymphocytes were added, one set of wells with HCT8 colorectal cancer cells was incubated for 2 hr with anti-ICAMI antibody (clone HA58, PharMingen). The MTT-labeled lymphocytes and colorectal cancer cells were then coincubated (30 min, 370C), washed, lysed, and read by spectrophotometry as stated above. The mean of S wells was recorded over 8 days at four different time points: days 1, 2, 5, and 8.
In Vitro Cell Proliferation To determine whether transduction of hepatoma cells with the ICAM-1 gene altered in vitro growth properties, cell proliferation assays were performed. Replicating rat hepatoma cells were exposed to HSV-hICAM1, HSVlac, or nothing at an MOI of 1 for 20 min at 370C. Cells were then plated in 24- (Fig. 3) .
In Vitro Cell Proliferation Cells transduced with HSV-hICAM1 grew similarly in culture compared to HSVlac-transduced cells and untreated cells, indicating that changes in in vivo tumor growth (below) cannot be accounted for by changes in intrinsic growth rate of the modified tumor (Fig. 4) .
In Vivo Tumorigenicity There was significantly decreased tumor growth in the left flanks of animals injected with HSVhICAM1-transduced cells compared to controls (Fig. 5) . Intrahepatic Vaccination Throughout the experiment, there was no difference in weight gain among treatment groups and all animals maintained normal grooming habits.
As illustrated in Figure 6 , there was significantly decreased uptake and growth of hepatic metastases in animals vaccinated with HSV-hICAMI cells compared to all controls (p c 0.05). There was no difference between animals vaccinated with HSVlac-transduced cells, radiated cells alone, or media.
Discussion
Stimulation of the host immune response against tumor antigens has shown great promise as an anticancer strategy. Systemic administration of cytokines such as IL-2 has shown efficacy in some patients with advanced malignancies, but use of IL-2 is limited by its significant toxicity (25, 26) . Gene therapy strategies utilizing genes coding for immunostimulatory cytokines such as IL-2, IL-4, IL-6, IL-7, TNF, IFN-,y and granulocyte-macrophage colony-stimuling factor (GM-CSF) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) Thus, there is a good biologic basis to support investigation of ICAM-1 gene transfer as immunomodulation in cancer therapy. Ultimately, however, human testing is necessary to determine utility of this approach; what is needed is a clinically useful delivery system for the human ICAM-1 gene. In this regard, our work adds significantly to these previously published studies in providing a clinically relevant system for testing the utility of ICAM-1 gene therapy in humans. In the present study, tumor cells were subjected to a single 20-min exposure to HSV vectors and tested for biological activity without selection for only the human ICAM-expressing cells. Despite the fact that only a percentage of cells was transduced, we were still able to induce significant binding of lymphocytes and to elicit an immunological reaction. We are able to reproduce all of the effects of ICAM-1 gene transfer seen in previous works by Wei et al. (1 5) without the time-consuming process of cell selection. Whether similar biologic effects can be seen in vivo and will be clinically useful awaits trials in humans.
HSV vectors are an excellent vector for use in gene therapy directed at cancer. This report extends prior findings from our laboratories and others (16, 17, 19, 21, 48) that HSV vectors are a rapid and efficient means of transferring genes of interest into dividing or nondividing cells. Transduction of tumor cells can be accomplished efficiently in 20 min and expression is relatively high for at least 1 week. A recent publication from our laboratories has demonstrated the feasibility of harvesting fresh tumor samples at operation, followed by radiation and successful transduction with HSV vectors to elicit high local production of secreted proteins such as IL-2 or GM-CSF (22) . The current study indicates that HSV-mediated gene transfer may also lead to high-level expression of cell surface proteins. Given the rapidity and efficiency of HSV-mediated gene transfer, a clinical vaccination protocol using these vectors appears imminently feasible.
Initial human trials using systemic immunostimulatory cytokines were done on patients who had extensive tumor burdens and no other treatment options. While some responses to immunotherapy were noted, complete responses were rare (49, 50) . Immunotherapy utilizing gene therapy for the treatment of cancer will likely be most effective in the treatment of microscopic or minimally residual tumor. Hepatic malignancy is a good model of microscopic residual disease because in most patients who undergo resection of tumor, disease recurs in the remnant liver, thus implicating residual microscopic hepatic disease at the time of operation as the cause for therapeutic failures. We investigated an intraportal vaccination strategy with hepatoma cells transduced with the human ICAM-1 gene and have demonstrated that this strategy can decrease growth of microscopic disease in the liver. In a similar rat hepatoma model, we have shown that by combining immunotherapy targeting macrophage activity with INF-,y and lymphocyte activity with IL-2 or GM-CSF, we can stimulate more effective antitumor immunity than either modality alone (21) . It is likely that a clinically relevant, immunostimulatory anti-cancer strategy will consist of multitargeted therapy. Some combination of tumor-expressed genes, including chemokines to attract immune cells to the tumor target, cell adhesion molecules to bind immune cells, and cytokines to activate the immune cells, holds promise. This report contributes to the evidence that the up-regulation of cell adhesion molecules using gene transfer strategies is a potentially useful method of binding immune cells at sites of tumor. These studies indicate that ICAM-1 is a therapeutic target and encourages studies combining induction of cell surface ICAM expression with other immunostimulatory strategies.
